Roth Capital raised the firm's price target on Aspen Aerogels to $5.75 from $3 and keeps a Buy rating on the shares after its Q1 results. While near-term visibility stays challenging given broader policy dynamics and a demand reset for key customer GM (GM), the firm sees underlying platform value longer-term, the analyst tells investors in a research note.
